Member Info for Bmhltd

Absolutely over the moon with that, now providing :

“sufficient working capital until December 2025 and be able to meet its financial covenants into September 2025.”

Also note the below long-only institutions—-should put the woolies up any shorters and also clearly very strong demand at a not terrible discount:

existing shareholders, including long-only institutional investors and family offices, as well as new investors. As the Issue Price was determined through the Bookbuild, it is the Board's assessment that the Issue Price has been determined on market terms, reflecting current market conditions and investor demand.

We march on now fully funded to Topline response rate readout, enough to see us through end of P2 FDA meeting when we will know exactly what we need to do for accelerated approvals and also P3 offering certainty for any would be partner / suitor…

Amazing news.

Agree Sax, we kind of expected this, I’m hoping the speed of this private placing and bearing in mind it will be to existing holders, they won’t want a large discount, as with the previous broader placing and it’s not for anyone to take place. See below.

Hoping £1.50 minimum and they get snapped up quickly. At the end of the day, unless they are buying them to flip, we have our P2 readout secured and post P2 meeting. I think we can rise soon after here and if I can buy anymore tomorrow I will be doing so, hopefully at a small discount to current price.

Should find out in next hours, or in the morning at the latest, the price realised for the placing.

Onwards and upwards.

Good luck all.

The Placing, in the form of accelerated book-building, reduces both execution and completion risk as it enables an equity raise efficiently and in a timely manner, typically with a lower discount to the current trading price, less exposure to market volatility, at a lower cost and with significantly reduced completion risk compared to a share issue enabling broader shareholder and investor participation. In the Placing, the Company is primarily targeting long-term institutional and other qualified investors due to their capability of offering substantial investments cost-effectively, at attractive terms. In particular, the rapidness of the Placing is considered as a significant advantage as it would provide the Company with funding prior to the forthcoming topline readout of Phase II BEXMAB trial and, consequently, continued operations and flexibility in pursuing the best commercial outcome in the partnering discussions. As indicated by the Company in the summer 2024, a rights issue or a broader share issue, the latter as organised by the Company in June 2024 enabling wider shareholder participation would be significantly more time-consuming and require resources from the Company which the Company does not currently have. The private placement structure is known to the market from previous funding actions of the Company. Based on an overall assessment, the Board considers the Placing to be the most favourable alternative for the Company to raise capital.

If it is the case we could really do with another big buyer stepping in and getting things moving back up as this is annoying but these prices will be a distant memory in April at the latest, AIMO….

No worries, basically weighing on the bid and tightening the spread to mask buying.

Only my synopsis.

Could also be a seller, gently dropping some, but I’m not sure that’s the case as suspect bid would be lower.

Order filling pretty much and trying to squeeze others out…

*Loading

Faron, Bex and Juho in the tech times.

The longer Faron remain independent and get the word out, the more value we should accrete in deal making, imo.

Could be close to a nibble, with Merck my best guess, having already taken out multiple companies pre-phase 2 top line data.

Suspect many are eyeing us up.

Seems they may have been running a companion molecular diagnostic in parallel which bodes well for results and the buzz across the industry will soon translate into a buzz in the share price, no doubt.

My personal feeling is institution(s) have been squeezing the book and losing up past few days, another small raise could be enough to see us in much better stead, or potentially a License Deal in Japan / Asia could be a good cash injection without selling the Farm.

Surely some grant funding and strategic equity is also possible.

GLA…

https://www.techtimes.com/articles/309271/20250203/united-unique-faron-pharmaceuticals-ceo-role-small-biotechs-advancing-unchartered-cancer.htm

*Second dose, at longest

A great end to the week, I was starting to wonder if they would get it across the line.

Even if they start dosing tomorrow that’s near enough for me and keeps the topline data readout on track.

IIRC Juho stated responses usually occur after second sore so around 6 weeks, then write the data up, much of which can be done in parallel as final data goes into statistical analysis.

You don’t need to be a genius to realise we are highly statistically sognificant here over no other treatment option and more than doubling o/s with deep durable responses.

Let’s gooooooooo!

Absolutely amazing news and more patients than I had anticipated- 35 r/r MDS patients and 20 frontline HR MDS patients.

Leaving the option open to continue to treat r/r MDS patients in the current protocol, to strengthen the data set further.

Given survival data is already trending way above 5-6 months r/r population with no further options I would be amazed if the FDA and MHRA didn’t see the ethical dilemma here in not expediting approval.

Bang on time and the excitement can now build into data / partnering / and if required, funding at a fair price.

Not long to go now….

Up the Faron!!!!!

Around 52 mins in.

Nice find Vares.

I’d have thought this would have got more airtime but I think he was more focussed on phase 3.

Still uber bullish here!

GLa

Where did I say it had anything to do with the stock price in Helsinki?

A forum full of negativity is hardly encouraging for new and existing investors wanting to share genuine company related information and news around the biotech / deal making space, relevant to Faron.

You enjoy dwelling in your own misery Gregg, trying to score cheap points over what you think another poster is talking about, those trying to share genuine, useful information….

I hear Samaritans is good for a moan and for cynical doom mongerers.

Exactly Sax, and there is far more data.

Feels like there are a significant number in here want to spread as much negativity as possible.

I for one, won’t be taking the bait.

GLA

If there is a raise, there’s no guarantees everyone can take part, so you run the risk of being shut out, potentially at a premium, with a potentially significant new investor…

Juho podcast 17/1/25

https://podcasts.apple.com/gb/podcast/citeline-podcasts/id923189836?i=1000684366569

Quiten down about a raise.

If there is, there is-more opportunity to buy more….

Juho will do a raise if he sees double / treble the value in doing one, thus seeing us through P2 RR readout for a dilution of c.10-15%.

In reality it doesn’t matter that much over time, and should be value accretive if the correct decision is made.

Constantly banging on about it spreads unnecessary fear among holders….

My comment. You’re the one disrespecting other posters research.

I’ll not bother from here on out.

I’ve done extensive research and based my valuations on previous buy outs within immunotherapy with applications in blood cancers & oncology seperately and combined.

I’ve also referenced why I think this and with some examples.

Don’t dismiss others research without offering something more comprehensive or I can’t take you seriously.

Regards

They already have the MATINS data.

I would be happy with £40-80 full takeover.

Really feel this could go for up to £120 though if we get a bidding war. c$15Bn.

The opportunity cost of waiting for piecemeal deals doesn’t compare,imo.

Anything below £40 and less than what forty seven was acquired for by Gilead would be to me a little disappointing but that cash position could play a role if we cannot get multiple bids.

Not long to wait. 3 months tops for data, imo.

Then offer soon after if not offer before…

Made a small addition of 1060 shares yesterday.

I really am bullish here and the only thing I feel that stands in the way of a mega deal is our cash position, but I feel this is mitigated by multiple interested parties, and we cannot rule out a partnership deal / opportunistic offer pre- data, the cash position becomes less of an issue and less likely to have us beholden to bullying tactics.

IMO & DYOR

That’s not to say if funds and institutions notice us and start to load up, and use their usual MO of squeezing the price and triggering sellers with a short ,to load up as cheap as possible there won’t be volatility beforehand.

GLA